New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
10:02 EDTSREV, TDC, HME, BMRN, SKM, ESRX, AT, KBW, ENR, ASEIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Science & Engineering (ASEI) downgraded to Hold from Buy at Benchmark Co.... Atlantic Power (AT) downgraded to Hold from Buy at Desjardins... BioMarin (BMRN) downgraded to Hold from Buy at Brean Capital... Energizer (ENR) downgraded to Market Perform from Outperform at Bernstein... Express Scripts (ESRX) downgraded to Hold from Buy at Jefferies... Home Properties (HME) downgraded to Underperform from Sector Perform at RBC Capital... KBW, Inc. (KBW) downgraded to Market Perform from Outperform at JMP Securities... SK Telecom (SKM) downgraded to Neutral from Outperform at Credit Suisse... ServiceSource (SREV) downgraded to Equal Weight from Overweight at Morgan Stanley... Teradata (TDC) downgraded to Sector Perform from Outperform at FBN Securities.
News For ASEI;AT;BMRN;ENR;ESRX;HME;KBW;SKM;SREV;TDC From The Last 14 Days
Check below for free stories on ASEI;AT;BMRN;ENR;ESRX;HME;KBW;SKM;SREV;TDC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
09:47 EDTESRXExpress Scripts' TriCare contract renewal removes an overhang, says UBS
UBS said Express Scripts successful renewal of the TriCare/Department of Defense PBM contract removes an overhang and should contribute 25c-30c to 2014 earnings. The firm expects shares to react positively and reiterates its Buy rating and $72 price target.
09:38 EDTESRXExpress Scripts TRICARE contract removes key overhang, says Citigroup
Citigroup believes the Express Scripts retaining the Department of Defense's TRICARE Pharmacy Program contract removes a key overhang on the stock and validates the company's business model. Citi reiterates a Buy rating on Express Scripts with a $92 price target.
April 19, 2014
18:41 EDTESRXExpress Scripts awarded 7-year TRICARE Pharmacy Program contract
Subscribe for More Information
April 17, 2014
17:02 EDTBMRNCatalyst Pharmaceutical, BioMarin in amended license agreement
Catalyst Pharmaceutical (CPRX) disclosed in a regulatory filing that on April 15, effective as of April 8, the company and BioMarin Pharmaceutical (BMRN) entered into Amendment No. 1 to License Agreement, amending in certain respects the License Agreement, dated October 26, 2012, between the company and BioMarin. The company intends to submit a FOIA Confidential Treatment Request to the SEC pursuant to Rule 24b-2 under the SEC Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Amendment. The omitted material will be included in the request for confidential treatment.
April 15, 2014
05:25 EDTENRHPC sector upgraded to Neutral from Cautious at Goldman
Subscribe for More Information
April 14, 2014
08:22 EDTBMRNBioMarin says FDA extends Kuvan market exclusivity by six months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use